Sangamo Therapeutics (SGMOQ) Cash from Investing Activities (2010 - 2025)

Sangamo Therapeutics' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$14000.0 for Q4 2025.

• On a quarterly basis, Cash from Investing Activities fell 101.06% year-over-year to -$14000.0 in Q4 2025; TTM through Dec 2025 was -$102000.0, a 100.27% decrease from a year earlier, with the FY2025 full-year figure at -$102000.0, down 100.27% from the prior year.
• Cash from Investing Activities grew to -$14000.0 in Q4 2025 per SGMOQ's latest filing, from -$64000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $89.3 million in Q2 2021 and bottomed at -$13.5 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is $35.7 million (2023), against an average of $26.2 million.
• Across the five-year window, Cash from Investing Activities jumped 1995.48% in 2023 and plunged 127.47% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $52.6 million in 2021, then dropped by 19.04% to $42.6 million in 2022, then declined by 11.51% to $37.7 million in 2023, then sank by 96.49% to $1.3 million in 2024, then tumbled by 101.06% to -$14000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Cash from Investing Activities figures stand at -$14000.0 (Q4 2025), -$64000.0 (Q3 2025), and -$24000.0 (Q2 2025).